What do you think?
Rate this book
Taxanes in Lung Cancer Therapy
Exploring topics from pharmacokinetics and tubulin targets to schedule dependence and clinical toxicity profiles, this timely work compiles-in a single source-current information on taxanes and their superior activity against small-cell and non-small-cell lung cancer that will enable researchers to optimize present and future palliative and curative strategies.
Representing international efforts to define the full potential of these chemotherapeutic drugs, Taxanes in Lung Cancer Therapy furnishes results from ongoing studies involving
novel mechanisms of action for paclitaxel and docetaxel
paclitaxel exposure duration as well as drug combinations and sequences
phase II trials with paclitaxel in chemotherapy-na ve advanced non-small-cell lung cancer (NSCLC) patients
the combination of paclitaxel and other active agents, such as cisplatin and ifosfamide, in previously untreated small-cell lung cancer (SCLC) as well as advanced NSCLC
comparisons of survival duration, response rates, and toxicity between taxol and other regimens
the activity of docetaxel against platinum-resistant/refractory NSCLC
and much more!
Written by researchers and clinicians at the forefront of the field, Taxanes in Lung Cancer Therapy is an essential resource for oncologists, pulmonologists, cancer researchers, pharmacologists, research and development personnel in the pharmaceutical industry, and graduate and medical school students in these disciplines.
Representing international efforts to define the full potential of these chemotherapeutic drugs, Taxanes in Lung Cancer Therapy furnishes results from ongoing studies involving
novel mechanisms of action for paclitaxel and docetaxel
paclitaxel exposure duration as well as drug combinations and sequences
phase II trials with paclitaxel in chemotherapy-na ve advanced non-small-cell lung cancer (NSCLC) patients
the combination of paclitaxel and other active agents, such as cisplatin and ifosfamide, in previously untreated small-cell lung cancer (SCLC) as well as advanced NSCLC
comparisons of survival duration, response rates, and toxicity between taxol and other regimens
the activity of docetaxel against platinum-resistant/refractory NSCLC
and much more!
Written by researchers and clinicians at the forefront of the field, Taxanes in Lung Cancer Therapy is an essential resource for oncologists, pulmonologists, cancer researchers, pharmacologists, research and development personnel in the pharmaceutical industry, and graduate and medical school students in these disciplines.
224 pages, Hardcover
First published April 1, 1998
Ratings & Reviews
Friends & Following
Create a free account to discover what your friends think of this book!
Community Reviews
No one has reviewed this book yet.